-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The persistence of remission in single-antigen-targeted chimeric antigen receptor (CAR) T cells is limited by antigen modulation, which can be overcome by combined targetin.
The primary endpoints of the study were toxicity and definitive dos.
A total of 20 B-ALL patients, aged 4 to 36 years, were recruited and all received CD12BBz therap.
The limited CAR T cell expansion and persistence of MSCV-CD12BBz compared to EF1a-CD2BBz prompted the laboratory to compare the promoters of EF1a and MSCV, but found no significant differenc.
In conclusion, this study demonstrates the safety and efficacy of CD12BBz in a CAYA B-ALL cohort, while further optimizing combinatorial antigen targeting to help overcome well-defined limitation.
Original source:
Shalabi Haneen, Qin Haiying, Su Angela et a.